Lanean...
Role of BRAF in Hepatocellular Carcinoma: A Rationale for Future Targeted Cancer Therapies
The few therapeutic strategies for advance hepatocellular carcinoma (HCC) on poor knowledge of its biology. For several years, sorafenib, a tyrosine kinase inhibitors (TKI) inhibitor, has been the approved treatment option, to date, for advanced HCC patients. Its activity is the inhibition of the re...
Gorde:
| Argitaratua izan da: | Medicina (Kaunas) |
|---|---|
| Egile Nagusiak: | , , , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2019
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6956203/ https://ncbi.nlm.nih.gov/pubmed/31766556 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/medicina55120754 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|